Annual General Meeting

28 Sep 2006

Chippenham, UK – 28 September 2006: Vectura Group plc (LSE: VEC) confirms that all resolutions put to the Annual General Meeting on 27 September were duly passed.

Enquiries

Vectura Group plc +44 (0) 1249 667 700
Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer

Financial Dynamics +44 (0) 207 831 3113
Sarah MacLeod/John Gilbert

Notes for Editors

About Vectura
Vectura's principal focus is the development of a range of inhaled drugs for the treatment both of lung diseases and other conditions where optimised delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura's products combine its proprietary, innovative, pulmonary formulation and device technologies (Aspirair® GyroHaler® and PowderHale®) with existing, off-patent drugs either for use in new indications or to provide inhalation as an improved route of administration. Using drugs that have already been approved in some form in at least one major pharmaceutical market lowers the risk of product development failure compared to new chemical entities, Vectura is able to secure patent protection for its portfolio by identifying new indications for off-patent compounds and applying the Company's proprietary delivery technologies to create new methods of administration. The Company has development collaborations with a number of companies, including Boehringer Ingelheim, Novartis, GSK and Chiesi and an un-named leading international pharmaceutical company. For further information, please visit Vectura's website at www.vectura.com.